Liposomes Delivery Systems Development Services

Antigen-presenting cells are an essential part of the immune response. Therefore, the improvement of cancer vaccines can start from the antigen presentation stage. Loading physiological ligands or simulating pathogens on the surface of liposomes that can target antigen-presenting cells such as DC can achieve customized target cell delivery.

The biggest advantage of therapeutic cancer vaccines is to enhance antigen-specific immunity against tumors. However, insufficient T cell activation and immune tolerance make the effect mediocre. Active targeting of lymph nodes through magnetic delivery of loaded antigen magnetic liposomes. Significant accumulation will occur at the target location, ultimately leading to an increase in the number of active DCs in lymph nodes and an increase in cytotoxic T lymphocytes (CTLs) within the tumor, which are associated with effective tumor growth inhibition.

Unlike peptides or proteins, nucleic acids have immunogenicity and do not require adjuvants. However, it is necessary to cross the cell membrane or nuclear membrane, and an effective delivery system is needed. Liposome encapsulation of nucleic acids mainly relies on electrostatic interactions. The negatively charged nucleic acid is wrapped on the surface of the bilayer lipid particles, and it undergoes electrostatic interaction with the newly positively charged bilayer lipid particles. Finally, multiple layers of particles are formed, where nucleic acid is captured between the two layers of lipid particles.

Peptide antigens have poor immunogenicity, and liposomes can serve as co-delivery systems for multiple substances. Liposomes can load different substances, so in addition to delivering antigen peptides, they can also load adjuvants, inhibitors, etc., while increasing the immunogenicity of peptide antigens and blocking immune checkpoints.